Tamoxifen: a drug that has to be switched on before it works
Tamoxifen is the drug people assume is doing its work the moment they swallow it. In fact most of the anti-cancer effect comes from something the body has to make out of it first, and one gene decides how much of that something appears.
Also sold as: Nolvadex, Soltamox.
What tamoxifen is
Tamoxifen is a hormone treatment for breast cancers that grow in response to oestrogen. It is taken daily, often for five to ten years, to lower the chance a cancer comes back, and it is also used to reduce risk in some people at high risk of the disease. It blocks the oestrogen signal that these tumours depend on.
Why your genes come into it
Tamoxifen itself is only weakly active. The body converts it into a far more potent metabolite called endoxifen, and CYP2D6 does the decisive step in that conversion. Someone with normal CYP2D6 activity produces the expected amount of endoxifen. Someone at the poor-metabolizer end produces much less from the same tablet, and the concern is that a weaker active exposure means a weaker anti-cancer effect. The research here is real but not settled, which is why CPIC frames it carefully: for poor metabolizers the guidance discusses whether a different class of drug, an aromatase inhibitor, is a better fit where a person's situation allows it, rather than declaring tamoxifen ineffective.
What published guidance says
The rows below restate CPIC's published guidance for each possible CYP2D6 result. They describe what an oncologist weighs when choosing between endocrine treatments, not a change for anyone to make alone. Tamoxifen is prescribed to lower the risk of a cancer returning, the alternatives carry their own trade-offs, and that balance belongs with the specialist who knows the tumour and the whole history.
CYP2D6
| If your CYP2D6 result is | What that means | Published CPIC guidance |
|---|---|---|
| Poor Metabolizer | Reduced formation of the active metabolite endoxifen. | CPIC: the guideline discusses considering an aromatase inhibitor where appropriate; confirm with your oncologist. |
| Intermediate Metabolizer | Somewhat reduced endoxifen formation. | CPIC: the guideline notes that intermediate metabolisers form somewhat less endoxifen than normal metabolisers; your oncologist can weigh whether this affects treatment choice. |
| Normal Metabolizer | Normal endoxifen formation. | CPIC: standard use per label. |
| Ultrarapid Metabolizer | Increased endoxifen formation. | CPIC: standard use per label. |
Can your DNA file answer this?
This is the same honest limit that applies to codeine, for the same reason. CYP2D6 is the one pharmacogene a genotyping chip cannot resolve: the gene sits beside near-identical pseudogenes and the variation that sets activity is structural, meaning whole-gene deletions, duplications and hybrid copies that an array of single positions cannot see. Aimosti therefore does not report CYP2D6 from a 23andMe or AncestryDNA file at all. It belongs to the Deep Read panel, which runs from aligned reads in a BAM or CRAM file, and even there a diplotype the reads do not settle is reported as Indeterminate. If a service offers a tamoxifen result from chip data, the data behind it cannot support the answer.
A genotyping chip reads only a few hundred thousand pre-selected positions, about 0.02% of your genome, chosen for common variation. It does not sequence the rest, so it cannot find the rare or novel pathogenic variants the clinical and carrier modules look for: a “no finding” from chip data means “this chip never looked”, far more so than with whole-genome sequencing. Chip data suits common-variant traits, pharmacogenomic tag SNPs, and haplogroup ancestry, not clinical or carrier screening.
Common questions
If I am a poor metabolizer, does that mean tamoxifen will not work for me?
No, and the guidance is careful not to say that. A poor-metabolizer result means less endoxifen is formed from a given dose, which is a reason for an oncologist to consider whether an aromatase inhibitor suits your case better. It is not evidence that tamoxifen has failed, and the studies linking CYP2D6 to outcomes are mixed enough that no one should stop treatment on a genotype alone.
Should I ask about switching to an aromatase inhibitor?
It is a reasonable question to raise, but the answer depends on things a genotype does not cover, including whether you have been through menopause, since aromatase inhibitors are used differently before and after it. That is exactly the kind of judgement the guidance leaves to the treating specialist rather than settling in a table.
Some medicines interfere with CYP2D6. Does that matter for tamoxifen?
It can, because a drug that strongly inhibits CYP2D6 can lower endoxifen just as a poor-metabolizer genotype does, and certain antidepressants are the classic example. It is a recognised prescribing consideration and a good reason to make sure whoever manages your tamoxifen has your full medication list.
Can I get this from my 23andMe file?
No, and Aimosti will not pretend otherwise. CYP2D6 needs aligned reads to call properly, so it is a Deep Read gene rather than a chip result. This is one of the clearest cases on the site of a question consumer array data cannot answer, which is why the coverage note says so plainly.